ConductScience.org, home

Comparison · NCT00385138-eb0d1fbe

Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm. Trial comparisons, record NCT00385138-eb0d1fbe. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00385138-eb0d1fbe

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01620.0120.0217wilson
Risk in group 20.01090.007630.0157wilson
Risk difference, group 1 minus group 20.00521-0.001070.0117newcombe hybrid score
Risk ratio, group 1 over group 21.480.9252.36log
Odds ratio, group 1 over group 21.480.9242.38log
Number needed to treat, for one more participant with the outcome on Cangrelor than on Clopidogrel192from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Cangrelor
cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
432,662OG000
Group 2Clopidogrelplacebo bolus \& infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion292,650OG001

Outcome

Type
SECONDARY
Title
Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm
Description
Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma \>/= 5 cm.
Time frame
randomization through 48 hours post randomization
Population
Safety population

Source ClinicalTrials.gov

Trial

Title
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
NCT number
NCT00385138
Phases
PHASE3
Conditions
Atherosclerosis, Acute Coronary Syndrome (ACS)
Interventions
Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
Lead sponsor
The Medicines Company
Results first posted
2014-04-21

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00385138-eb0d1fbe